GlassScriptPhysician profile
Amanjit K Dhatt
NPI 1811973795
$3,790.41
in general payments reported to CMS, 2019-2025
26 companies · $932 in 2025
The $932 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $225 · 2021: $485 · 2022: $286 · 2023: $358 · 2024: $555 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,698 · Education: $108 · Consulting Fee: $39.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,698.49 |
| Education | $107.50 |
| Consulting Fee | $39.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $636.14 | 2020-2025 | Hyqvia, Cuvitru, Takhzyro |
| Glaxosmithkline, LLC. | $606.68 | 2019-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $536.89 | 2019-2025 | Dupixent |
| Genzyme Corporation | $272.39 | 2019-2025 | |
| Pharming Healthcare, INC. | $227.69 | 2019-2024 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.18 | 2019-2021 | |
| Csl Behring | $169.57 | 2019-2024 | Hizentra, Haegarda |
| Astrazeneca Pharmaceuticals LP | $147.86 | 2019-2021 | |
| Edwards Lifesciences Corporation | $128.73 | 2025 | Sapien 3 Ultra Resilia |
| Octapharma USA, INC. | $128.49 | 2021-2024 | Cutaquig |
| Sanofi-Aventis U.S. LLC | $106.81 | 2021-2022 | |
| Shire North American Group INC | $93.32 | 2019 | |
| Kaleo, INC. | $91.66 | 2019-2022 | |
| Pfizer INC. | $83.37 | 2021-2024 | |
| Biocryst US Sales Co., LLC | $79.81 | 2021-2025 | Orladeyo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $58.03 | 2021 | |
| Adma Biomanufacturing LLC | $39.40 | 2025 | |
| Optinose US, INC. | $35.57 | 2019-2023 | |
| Amgen INC. | $34.00 | 2025 | |
| Blueprint Medicines Corporation | $27.29 | 2023 | Ayvakit |
| Alk-Abello, INC | $23.46 | 2019 | |
| Sunovion Pharmaceuticals INC. | $20.93 | 2019 | |
| Hospira, INC. | $20.80 | 2021 | |
| Grifols USA, LLC | $19.10 | 2022 | |
| Ionis Pharmaceuticals, INC. | $16.31 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanjit Dhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.